Brief: Galera Submits Marketing Application For Oral Mucositis Drug
Dec 12 (Reuters) - Galera Therapeutics Inc GRTX.O :
* GALERA SUBMITS NEW DRUG APPLICATION FOR AVASOPASEM FOR
SEVERE
ORAL MUCOSITIS
* GALERA THERAPEUTICS INC- FDA HAS GRANTED FAST TRACK AND
BREAKTHROUGH THERAPY DESIGNATIONS TO AVASOPASEM FOR REDUCTION OF
SOM INDUCED BY RADIOTHERAPY
* GALERA THERAPEUTICS INC- AVASOPASEM WAS GENERALLY WELL
TOLERATED
COMPARED TO PLACEBO
Source text for Eikon: ID:nGNX2qq62f
Further company coverage: GRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galera Therapeutics
See all newsBrief: Galera Therapeutics Says Nasdaq Will Delist Co's Common Stock By Filing Form 25 With SEC On Sept 4
Brief: Galera Announces Board Approval Of Complete Liquidation And Dissolution
Brief: Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To Delist Co’s Shares
Brief: Alpha Pharma Investments Llc Reports 10.899% Passive Stake In Galera Therapeutics
Brief: Galera Adopts Limited Duration Stockholder Rights Agreement